Reampla 125 mg Capsules by Pfizer is a cutting-edge oral treatment containing the active ingredient Palbociclib. Reampla 125 mg Palbociclib is primarily indicated for the treatment of certain types of breast cancer. Specifically, Reampla 125 mg is used in combination with hormone therapy to manage hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer in postmenopausal women and men.
Reampla 125 mg Capsules Palbociclib belong to a class of drugs called CDK4/6 inhibitors, which work by blocking proteins known as cyclin-dependent kinases (CDK4 and CDK6). These proteins are responsible for promoting the growth and division of cancer cells. By inhibiting CDK4/6, Reampla 125 mg Palbociclib helps slow down or stop the progression of breast cancer, enhancing overall survival rates and improving patients’ quality of life.
Reampla 125 mg Palbociclib Capsules are widely recognized as a vital part of advanced breast cancer treatment regimens worldwide due to their effectiveness and patient-friendly oral administration.
🔥 Key Benefits & Uses of Reampla 125 mg Palbociclib:
- Advanced Breast Cancer: Reampla 125 mg Palbociclib is used alongside aromatase inhibitors like Letrozole or Fulvestrant for treating HR+/HER2- advanced or metastatic breast cancer.
- Targeted Cancer Therapy: Reampla 125 mg targets CDK4 and CDK6 proteins, effectively slowing tumor progression.
- Combination Therapy: Reampla 125 mg is proven to enhance the efficacy of hormonal therapies in controlling advanced breast cancer.
- Oral Administration: Reampla 125 mg Capsules are taken orally, providing convenience and flexibility for patients undergoing long-term cancer treatment.
- Improved Survival: Clinical studies demonstrate that Reampla 125 mg significantly extends progression-free survival in patients with advanced breast cancer.
💊 How to Use Reampla 125 mg Palbociclib:
- Dosage: Typically, Reampla 125 mg is taken once daily for 21 consecutive days, followed by a 7-day break (28-day cycle).
- Combination: Reampla 125 mg Palbociclib is used in combination with hormone therapy (Letrozole or Fulvestrant).
- Administration: Take Reampla 125 mg Capsules with food at the same time each day. Swallow the capsule whole without crushing or chewing.
- Missed Dose: If a dose of Reampla 125 mg is missed, do not take an extra dose; resume the regular schedule the next day.
🧊 Storage Instructions:
- Store Reampla 125 mg Capsules below 30°C.
- Keep Reampla 125 mg Palbociclib in its original packaging to protect from moisture and light.
- Keep out of reach of children.
⚠️ Potential Side Effects of Reampla 125 mg Palbociclib:
- Neutropenia (low white blood cell count).
- Fatigue and weakness.
- Nausea, vomiting, or diarrhea.
- Hair thinning or hair loss.
- Infections or fever.
Patients experiencing severe side effects while using Reampla 125 mg Palbociclib should consult their healthcare provider immediately.
🌍 Why Choose Reampla 125 mg Palbociclib by Pfizer?
- Manufactured by Pfizer, a globally trusted pharmaceutical leader.
- Proven effectiveness in HR+/HER2- advanced breast cancer.
- Convenient once-daily oral capsule.
- Improves patient survival and quality of life.
- Widely prescribed as a first-line treatment for advanced breast cancer.
✅ Real Patient Reviews:
“After being diagnosed with metastatic breast cancer, Reampla 125 mg Palbociclib became a life-changing part of my treatment. It slowed my cancer progression and gave me hope.” – Patient Testimonial
🔗 Official Resource:
Pfizer Official Website – For detailed prescribing information and patient resources.
Değerlendirmeler
Henüz değerlendirme yapılmadı.